ArticleHuman vaccines & immunotherapeutics2015
Small molecule drugs with immunomodulatory effects in cancer.
Article in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Bidirectional effects of the tryptophan metabolite indole-3-acetaldehyde on colorectal cancer.World journal of gastrointestinal oncology · 2024Article
- Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.Advances in experimental medicine and biology · 2024Review
- Genetically engineered cellular nanoparticles for biomedical applications.Biomaterials · 2023Review
- Microbial metabolites are involved in tumorigenesis and development by regulating immune responses.Frontiers in immunology · 2023Review
- Targeting Breast Cancer Stem Cells.International journal of biological sciences · 2023Review
- Dual Role of Indoles Derived From Intestinal Microbiota on Human Health.Frontiers in immunology · 2022Review
- Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy.Cancer immunology research · 2021Article
- A Special View of What Was Almost Forgotten: p38δ MAPK.Cancers · 2021Review
- Targeting Dietary and Microbial Tryptophan-Indole Metabolism as Therapeutic Approaches to Colon Cancer.Nutrients · 2021Review
- Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.Advances in experimental medicine and biology · 2021Article
- Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.Journal for immunotherapy of cancer · 2020Article
- Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.Journal for immunotherapy of cancer · 2019Review
- IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.The Journal of clinical investigation · 2019Article
- Article
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.Frontiers in pharmacology · 2019Review
- Remote Control of Mammalian Cells with Heat-Triggered Gene Switches and Photothermal Pulse Trains.ACS synthetic biology · 2018Article
- Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.Biotechnology journal · 2018Review
- Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.Acta pharmacologica Sinica · 2017Article
- Immunology: Mind the immuno-connection gap.Nature chemical biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy shows promise for positively changing the landscape of the management of many advanced solid tumors, including gastrointestinal (GI) malignancies. Many of these developments have been focused on vaccine-based, monoclonal antibody therapies and more recently, checkpoint inhibitors, although many small molecule inhibitors can function as immunomodulators. Small molecule compounds have several advantages over conventional immunotherapeutic agents including: ease of production and the potential for oral administration. There is a potential niche for small molecule immunomodulators to enhance the efficacy of existing immunotherapeutic and cytotoxic agents. This article focuses on two categories of small molecule compounds with immunomodulatory effects: IDO and MEK inhibitors. Indoleamine -2, 3- dioxygenase (IDO) is known for its effects in tumor immunity. IDO inhibitors are generally well-tolerated and have the potential to enhance anti-tumor responses when combined with checkpoint inhibitors. MEK inhibitors affect signal transduction of the RAS-RAF-MEK pathway and numerous MEK inhibitors are currently being investigated in solid tumors. Small molecule immunomodulators are currently being investigated for their potential role in augmenting the effects of conventional immunotherapeutic agents although further research is required to identify those patients most likely to respond to combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.